Merck, Inc.
🇵🇭Philippines
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)
Phase 3
Terminated
- Conditions
- HIV Infection
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 355
- Registration Number
- NCT00443729
RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)
Phase 3
Completed
- Conditions
- Meningitis, MeningococcalRotavirus Infections
- Interventions
- Biological: RotaTeq®Biological: NeisVac-C®
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 247
- Registration Number
- NCT00443846
Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)
Phase 3
Completed
- Conditions
- Migraine
- Interventions
- Drug: Telcagepant 300 mg soft gel capsulesDrug: Rizatriptan 10 mg tabletsDrug: Telcagepant 280 mg tabletsDrug: Placebo to telcagepant capsulesDrug: Placebo to rizatriptan tabletsDrug: Placebo to telcagepant tablets
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1068
- Registration Number
- NCT00443209
Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Phase 3
Completed
- Conditions
- Migraine
- Interventions
- Drug: Telcagepant potassium 150 mgDrug: Telcagepant potassium 300 mgDrug: Zolmitriptan 5 mgDrug: Placebo to tecagepant 300 mgDrug: Placebo to telcagepant 150 mgDrug: Placebo to zolmitriptan 5 mgDrug: Rescue medication
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1380
- Registration Number
- NCT00442936
Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)
Phase 2
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 99
- Registration Number
- NCT00441701
The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)
Phase 3
Terminated
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: PegIntron (peginterferon alfa-2b)Drug: Rebetol (ribavirin)
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 117
- Registration Number
- NCT00441584
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
Phase 3
Completed
- Conditions
- Haemophilus Influenzae Type BHepatitis B
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2015-03-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 546
- Registration Number
- NCT00441012
Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)
Phase 3
Completed
- Conditions
- Hepatitis B
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00440531
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
Phase 3
Completed
- Conditions
- Hepatitis B Virus Infection
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 277
- Registration Number
- NCT00440297
Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)
Phase 2
Completed
- Conditions
- AndrogensHypogonadism
- Interventions
- Drug: PlaceboDrug: Oral testosterone undecanoate (Andriol)
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 322
- Registration Number
- NCT00434824
© Copyright 2025. All Rights Reserved by MedPath